JP2019503985A - モノクローナル抗体、造血幹細胞の産生のための方法および組成物、ならびにそれらを使用する方法 - Google Patents

モノクローナル抗体、造血幹細胞の産生のための方法および組成物、ならびにそれらを使用する方法 Download PDF

Info

Publication number
JP2019503985A
JP2019503985A JP2018522547A JP2018522547A JP2019503985A JP 2019503985 A JP2019503985 A JP 2019503985A JP 2018522547 A JP2018522547 A JP 2018522547A JP 2018522547 A JP2018522547 A JP 2018522547A JP 2019503985 A JP2019503985 A JP 2019503985A
Authority
JP
Japan
Prior art keywords
cells
hsc
antibody
hscs
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018522547A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019503985A5 (https=
Inventor
ジョン エル． マグナニ，
ジョン エル． マグナニ，
Original Assignee
グリコミメティクス， インコーポレイテッド
グリコミメティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グリコミメティクス， インコーポレイテッド, グリコミメティクス， インコーポレイテッド filed Critical グリコミメティクス， インコーポレイテッド
Publication of JP2019503985A publication Critical patent/JP2019503985A/ja
Publication of JP2019503985A5 publication Critical patent/JP2019503985A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
JP2018522547A 2015-11-03 2016-11-02 モノクローナル抗体、造血幹細胞の産生のための方法および組成物、ならびにそれらを使用する方法 Pending JP2019503985A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562250424P 2015-11-03 2015-11-03
US62/250,424 2015-11-03
PCT/US2016/060014 WO2017079215A1 (en) 2015-11-03 2016-11-02 Methods and compositions for the production of monoclonal antibodies, hematopoietic stem cells, and methods of using the same

Publications (2)

Publication Number Publication Date
JP2019503985A true JP2019503985A (ja) 2019-02-14
JP2019503985A5 JP2019503985A5 (https=) 2019-12-12

Family

ID=57539587

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018522547A Pending JP2019503985A (ja) 2015-11-03 2016-11-02 モノクローナル抗体、造血幹細胞の産生のための方法および組成物、ならびにそれらを使用する方法

Country Status (6)

Country Link
US (1) US20180320136A1 (https=)
EP (1) EP3371222A1 (https=)
JP (1) JP2019503985A (https=)
CN (1) CN108350077A (https=)
CA (1) CA3002880A1 (https=)
WO (1) WO2017079215A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110755608A (zh) * 2018-07-27 2020-02-07 上海微创医疗器械（集团）有限公司 一种特异性抗体的用途、一种植入医疗器械及其制备方法
CN109053892B (zh) * 2018-09-19 2021-03-26 苏州思坦维生物技术股份有限公司 特异结合人及猴cd38抗原的单克隆抗体及其制备方法与应用
WO2020158943A1 (ja) * 2019-02-01 2020-08-06 住友化学株式会社 抗体及びその機能性断片
US20240075063A1 (en) * 2020-12-10 2024-03-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of mait cells for controlling graft versus host disease

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965457A (en) * 1995-06-06 1999-10-12 Magnani; John L. Methods of screening for a candidate compound able to bind to CD34+ cells
JP2001517427A (ja) * 1997-09-25 2001-10-09 グリコテック コーポレイション 造血幹細胞を結合するための方法および組成物
WO2009020201A1 (ja) * 2007-08-08 2009-02-12 Kyowa Hakko Kirin Co., Ltd. 単離された細胞集団
JP2010516240A (ja) * 2007-01-18 2010-05-20 スオメン プナイネン リスティ，ヴェリパルベル ヒト細胞からの新規の炭水化物、ならびにその分析および修飾のための方法
JP2011504099A (ja) * 2007-11-09 2011-02-03 スオメン プナイネン リスティ，ヴェリパルベル シアリルルイスｃ、シアリルＴｎ、及びＮ−グリコリルノイラミン酸のエピトープに関連づけられるヒトモノクローナル抗体、ならびに前記エピトープを含む幹細胞の分析方法
WO2012039430A1 (ja) * 2010-09-21 2012-03-29 株式会社Ｇｐバイオサイエンス がん幹細胞の単離方法
WO2012045913A1 (en) * 2010-10-06 2012-04-12 Suomen Punainen Risti, Veripalvelu Method for isolating cells and a cell population thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4289747A (en) 1978-12-26 1981-09-15 E-Y Laboratories, Inc. Immunological determination using lectin
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5130144B1 (en) 1984-02-06 1995-08-15 Univ Johns Hopkins Human stem cells and monoclonal antibodies
US4965204A (en) 1984-02-06 1990-10-23 The Johns Hopkins University Human stem cells and monoclonal antibodies
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
FR2596413B1 (fr) 1986-03-27 1988-06-10 Merieux Inst Nouveaux milieux de culture de bacteries appartenant au genre bordetella, contenant des derives etherifies de polymeres de d-glucose, et leur application
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5536475A (en) 1988-10-11 1996-07-16 Baxter International Inc. Apparatus for magnetic cell separation
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1993015722A1 (en) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
US5908782A (en) 1995-06-05 1999-06-01 Osiris Therapeutics, Inc. Chemically defined medium for human mesenchymal stem cells
US5719867A (en) 1995-06-30 1998-02-17 Scientific-Atlanta, Inc. Plural telephony channel baseband signal demodulator for a broadband communications system
US6043348A (en) * 1996-11-13 2000-03-28 Lawman; Michael J. P. Antibody recognizing a small subset of human hematopoietic cells
AU4336599A (en) 1998-06-08 1999-12-30 Osiris Therapeutics, Inc. (in vitro) maintenance of hematopoietic stem cells
DK1141028T3 (da) 1998-12-23 2010-05-25 Pfizer Humane monoklonale antistoffer til CTLA-4
IL148079A0 (en) 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
US20100145032A1 (en) * 2007-01-18 2010-06-10 Suomen Punainen Risti, Veripalelu Novel carbohydrate profile compositions from human cells and methods for analysis and modification thereof
US20110052574A1 (en) * 2007-12-06 2011-03-03 Csl Limited Method of inhibition of leukemic stem cells
FI20095459A0 (fi) * 2009-04-24 2009-04-24 Suomen Punainen Risti Veripalv Uusia määritysmenetelmiä
WO2010132315A1 (en) * 2009-05-13 2010-11-18 Endgenitor Technologies, Inc. Enhanced hematopoietic stem cell engraftment
US8464599B2 (en) 2011-01-10 2013-06-18 GM Global Technology Operations LLC Eight speed dual clutch transmission

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965457A (en) * 1995-06-06 1999-10-12 Magnani; John L. Methods of screening for a candidate compound able to bind to CD34+ cells
JP2001517427A (ja) * 1997-09-25 2001-10-09 グリコテック コーポレイション 造血幹細胞を結合するための方法および組成物
JP2010516240A (ja) * 2007-01-18 2010-05-20 スオメン プナイネン リスティ，ヴェリパルベル ヒト細胞からの新規の炭水化物、ならびにその分析および修飾のための方法
WO2009020201A1 (ja) * 2007-08-08 2009-02-12 Kyowa Hakko Kirin Co., Ltd. 単離された細胞集団
JP2011504099A (ja) * 2007-11-09 2011-02-03 スオメン プナイネン リスティ，ヴェリパルベル シアリルルイスｃ、シアリルＴｎ、及びＮ−グリコリルノイラミン酸のエピトープに関連づけられるヒトモノクローナル抗体、ならびに前記エピトープを含む幹細胞の分析方法
WO2012039430A1 (ja) * 2010-09-21 2012-03-29 株式会社Ｇｐバイオサイエンス がん幹細胞の単離方法
WO2012045913A1 (en) * 2010-10-06 2012-04-12 Suomen Punainen Risti, Veripalvelu Method for isolating cells and a cell population thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BITAN, MENACHEM ET AL., EXPERIMENTAL HEMATOLOGY, vol. 33, no. 6, JPN6020036112, 23 May 2005 (2005-05-23), pages 713 - 718, ISSN: 0004498339 *
ZHOU, FENGBIAO ET AL., THE JOURNAL OF BIOCHEMISTRY, vol. 148, no. 3, JPN6020036113, 15 June 2010 (2010-06-15), pages 273 - 280, ISSN: 0004355100 *

Also Published As

Publication number Publication date
CN108350077A (zh) 2018-07-31
WO2017079215A1 (en) 2017-05-11
US20180320136A1 (en) 2018-11-08
EP3371222A1 (en) 2018-09-12
CA3002880A1 (en) 2017-05-11

Similar Documents

Publication Publication Date Title
JP2022106807A (ja) Ｃｄ１１７＋細胞を枯渇させるための組成物及び方法
US20240207428A1 (en) Compositions and methods for the depletion of cells
CA2831336C (en) T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2
JP2022501428A (ja) 抗ｌｉｌｒｂ２抗体およびその使用の方法
KR20210058811A (ko) 고친화도, 이소형-선택적 TGFβ1 억제제 및 그의 용도
JP2004538490A (ja) 体性幹細胞の同定および単離ならびにその使用
BR112017014361B1 (pt) Uso de uma população de células-tronco mesenquimais (MSCS) modificadas com fucosiltransferase VI (FTVI) que expressa o ligante de E-L Selectina de célula hematopoiética (HCELL) para tratar diabetes
JPH05503632A (ja) モノクローナル抗体ｍ１９５の超可変領域の治療的使用およびその構築
CN108285483B (zh) 用于中风和缺血或缺血性病况的人抗体及其特异性结合序列
JP2019503985A (ja) モノクローナル抗体、造血幹細胞の産生のための方法および組成物、ならびにそれらを使用する方法
JP2024023226A (ja) 造血幹細胞及び前駆細胞を動員させるための投薬レジメン
CA3255414A1 (en) TREATMENT FOR MYELOID DISORDERS AND ACUTE LEUKEMIAS TARGETING NEW TUMOR-SPECIFIC ANTIGENS
TW202244060A (zh) 免疫調節抗體及其用途
ES2299590T3 (es) Uso medico de celulas madre que expresan vegfr-1.ng vegfr-1.
WO2023208157A1 (zh) 靶向cd19的嵌合抗原受体及其应用
US10961308B2 (en) Embigin inhibition for promotion of hematopoietic stem and progenitor cell expansion
WO2024131861A1 (en) Bispecific antibodies targeting cd117 and cd3
CA3137568A1 (en) Compositions and methods of immunodepletion for the treatment of malignant and non-malignant hematological diseases
HK40129668A (zh) 靶向cd117和cd3的双特异性抗体
WO2018150066A1 (es) Uso de moduladores de la función de cd69 para la movilización y proliferación de precursores hematopoyéticos
WO2025061028A1 (zh) 一种修饰细胞的方法及其应用
US20220296727A1 (en) Immunoconjugate
JP2024542027A (ja) 細胞標的療法を利用したがんの治療及び関連する研究プロトコル
JP2018533586A (ja) がん幹細胞を標的にし、そして侵襲性がんを処置するための抗体
HK40091146A (zh) 改善细胞治疗的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191101

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191101

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200916

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200929

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210430